Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.

OBJECTIVES The aim of this study was to develop and validate a population pharmacokinetic model in order to describe ritonavir-boosted saquinavir concentrations dosed twice and once daily in human immunodeficiency virus (HIV)-infected patients from the UK, Uganda and Thailand and to identify factors that may influence saquinavir pharmacokinetics. METHODS Pharmacokinetic data from 10 clinical studies were combined. Non-linear mixed effects modelling (NONMEM version V) was applied to determine the saquinavir pharmacokinetic parameters, interindividual/interoccasion variability (IIV/IOV) and residual error. Various covariates potentially related to saquinavir pharmacokinetics were explored, and the final model was validated by means of 95% prediction interval and testing the predictive performance of the model with data not included in the model-building process. RESULTS Ninety-seven patients were included from the UK (n = 52), Uganda (n = 18) and Thailand (n = 27), contributing 347 saquinavir profiles (1-14 profiles per patient). A one-compartment model with zero-order absorption and lag-time best described the data with IIV/IOV on apparent oral clearance (CL/F) and volume of distribution (V/F) and with IIV on duration and absorption lag-time. The ritonavir area under the curve over the dosing interval was significantly associated with saquinavir CL/F and V/F. A typical patient from the UK had approximately 1.5- and 3-fold higher saquinavir CL/F compared with patients from Uganda (89.0 versus 49.8 L/h) and Thailand (89.0 versus 26.7 L/h), respectively. CONCLUSIONS A model to characterize ritonavir-boosted saquinavir pharmacokinetics in HIV-infected adults has been developed and validated. The model could be used for dosage adaptation following therapeutic drug monitoring and to assess patients' suitability for once-daily boosted saquinavir therapy.

[1]  L. Aarons,et al.  Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. , 2008, The Journal of antimicrobial chemotherapy.

[2]  B. Gazzard,et al.  Pharmacokinetics and Safety of Saquinavir/Ritonavir and Omeprazole in HIV‐infected Subjects , 2008, Clinical pharmacology and therapeutics.

[3]  Marc Lavielle,et al.  Estimation of Population Pharmacokinetic Parameters of Saquinavir in HIV Patients with the MONOLIX Software , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[4]  B. Gazzard,et al.  Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses. , 2006, AIDS research and human retroviruses.

[5]  S. Khoo,et al.  An Update on Therapeutic Drug Monitoring for Antiretroviral Drugs , 2006, Therapeutic drug monitoring.

[6]  J. Schapiro,et al.  Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. , 2006 .

[7]  S. Khoo,et al.  Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[8]  J. Ananworanich,et al.  Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. , 2005, The Journal of antimicrobial chemotherapy.

[9]  V. Soriano,et al.  Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral‐experienced HIV‐infected patients , 2005, Journal of medical virology.

[10]  John Urquhart,et al.  Successful Projection of the Time Course of Drug Concentration in Plasma During a 1‐Year Period From Electronically Compiled Dosing‐Time Data Used as Input to Individually Parameterized Pharmacokinetic Models , 2005, Journal of clinical pharmacology.

[11]  B. Gazzard,et al.  Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily. , 2005, The Journal of antimicrobial chemotherapy.

[12]  F. van Leth,et al.  Nevirapine and Efavirenz Pharmacokinetics and Covariate Analysis in the 2Nn Study , 2005, Antiviral therapy.

[13]  Lewis B. Sheiner,et al.  Some suggestions for measuring predictive performance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[14]  B. Gazzard,et al.  Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. , 2005, British journal of clinical pharmacology.

[15]  James Curran,et al.  Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach , 2005 .

[16]  B. Gazzard,et al.  Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1–Infected Patients , 2004, Journal of acquired immune deficiency syndromes.

[17]  B. Hirschel,et al.  Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. , 2004, The Journal of antimicrobial chemotherapy.

[18]  B. Gazzard,et al.  Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen , 2004, AIDS.

[19]  D. Katzenstein,et al.  Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. , 2004, The Journal of infectious diseases.

[20]  Pascal Pernet,et al.  Enhanced Saquinavir Exposure in Human Immunodeficiency Virus Type 1-Infected Patients with Diarrhea and/or Wasting Syndrome , 2004, Antimicrobial Agents and Chemotherapy.

[21]  B. Gazzard,et al.  Pharmacokinetics of Once-Daily Saquinavir/Ritonavir in HIV-Infected Subjects: Comparison with the Standard Twice-Daily Regimen , 2003, Antiviral therapy.

[22]  David J. Lunn,et al.  The Pharmacokinetics of Saquinavir: A Markov Chain Monte Carlo Population Analysis , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[23]  D. Burger,et al.  Simultaneous Determination of the HIV Drugs Indinavir, Amprenavir, Saquinavir, Ritonavir, Lopinavir, Nelfinavir, the Nelfinavir Hydroxymetabolite M8, and Nevirapine in Human Plasma by Reversed-Phase High-Performance Liquid Chromatography , 2003, Therapeutic drug monitoring.

[24]  K. Ruxrungtham,et al.  Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. , 2003, The Journal of antimicrobial chemotherapy.

[25]  M. Kurowski,et al.  Pharmacokinetic and tolerability profile of twice‐daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers , 2003, HIV medicine.

[26]  K. Ruxrungtham,et al.  Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects. , 2003, Journal of acquired immune deficiency syndromes.

[27]  G. Plosker,et al.  Saquinavir: a review of its use in boosted regimens for treating HIV infection. , 2003, Drugs.

[28]  V. Soriano,et al.  Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir. , 2002, AIDS.

[29]  R. Haubrich,et al.  Therapeutic drug monitoring in HIV infection: current status and future directions , 2002, AIDS.

[30]  T. Blaschke,et al.  Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy , 1997, Antimicrobial agents and chemotherapy.